The Invitae Pediatric Hematologic Malignancies Panel analyzes genes associated with a hereditary predisposition to develop childhood hematologic malignancies. These genes were selected based on the available evidence to date to provide Invitae’s most comprehensive childhood-onset hereditary hematologic malignancies panel. Some of these genes are also associated with an increased risk of other cancer types.
Recent studies of pediatric cancer patients have reported predisposing pathogenic variants in a number of heritable genes. The results show that approximately 10% of children who develop cancer have an underlying cancer predisposing condition. Genetic testing of these genes may confirm a diagnosis and can substantially influence the choice of appropriate screening and medical management options for the child and other relatives. This test is specifically designed for heritable germline mutations and is not appropriate for the detection of somatic mutations.
If the patient has undergone a bone marrow transplant from a donor (allogenic) prior to genetic testing or has a current hematological malignancy with actively circulating tumor cells, testing a sample type not derived from blood (such as skin biopsy) is recommended. While we do not accept this sample type directly, we can accept gDNA derived from skin or muscle, though deletion/duplication analysis is not guaranteed because the success rate varies based on sample quality. Please see our Sample requirements page for more details.
ATM BLM CEBPA EPCAM GATA2 HRAS MLH1 MSH2 MSH6 NBN NF1 PMS2 RUNX1 TERC TERT TP53
ATM BLM CEBPA EPCAM GATA2 HRAS MLH1 MSH2 MSH6 NBN NF1 PMS2 RUNX1 TERC TERT TP53
Inherited bone marrow failure syndromes (IBMFS) are a group of multisystemic disorders characterized by abnormal bone marrow production (aplastic anemia, thrombocytopenia, neutropenia), other clinical features, and increased risk of hematologic malignancy development. For patients with features suggestive of IBMFS, please see the Invitae Bone Marrow Failure Syndromes Panel for more details.
RASopathies are a class of pediatric developmental disorders that share a common spectrum of symptoms, including congenital heart defects, short stature, distinctive craniofacial features, and a predisposition to malignancies, such as juvenile myelomonocytic leukaemia (JMML) and embryonal rhabdomyosarcoma. For patients with features suggestive of a RASopathies condition, please see the Invitae RASopathies Comprehensive Panel for more details.
Advances in genetic testing and studies of pediatric cancer patients have reported predisposing pathogenic genetic variants in a number of heritable genes. Identification of a hereditary cancer predisposition in childhood or adolescence can substantially influence the choice of appropriate screening and medical management options for the child and other relatives.
Cases of early-onset hematologic malignancies in children or young adults may be associated with underlying hereditary predisposition syndromes. Blood-related cancers may present with other prominent clinical features as part of the spectrum of a particular genetic syndrome. Non-syndromic familial myelodysplastic syndrome (MDS)/acute myelogenous leukemia (AML) is characterized by a strong family history of MDS or AML without other apparent phenotypic features. Most cases are caused by inheriting a pathogenic variant in a gene encoding a transcription factor critical for hematopoiesis. Familial occurrences of MDS/AML appear to be rare, but may be underdiagnosed.
Determination of an underlying genetic predisposition in an individual with a personal or family history of a hematologic malignancy is critical for the selection of therapy regimens, consideration of bone marrow or stem cell transplant, long-term cancer surveillance and prognosis and counseling of the individual and their family.
Individuals with a pathogenic variant in one of these genes have an increased risk of malignancy compared to the average person, but not everyone with such a variant will actually develop cancer. Further, the same variant may manifest with different symptoms, even among family members. Because we cannot predict which cancers may develop, additional medical management strategies focused on cancer prevention and early detection may be beneficial. For gene-associated cancer risks, see the tables below.
|Genes||Condition||Hematologic malignancy||References (PMIDs)|
|ATM||Ataxia-telangiectasia||Acute lymphoblastic leukemia (ALL)||3459930, 12673804|
|BLM||Bloom syndrome||ALL, acute myeloid leukemia (AML), lymphoma||9062585|
|CEBPA||Familial acute myeloid leukemia (AML) with mutated CEBPA||AML||26162409|
|EPCAM||non-Hodgkin’s lymphoma, ALL, AML||18709565, 16341812, 24737826|
|GATA2||GATA2 deficiency||myelodysplastic syndrome (MDS), AML||24227816, 24345756|
|HRAS||Costello syndrome||ALL||25742478, 21500339|
|MLH1||Constitutional mismatch repair deficiency syndrome (CMMR-D)||non-Hodgkin’s lymphoma, ALL, AML||18709565, 16341812, 24737826|
|MSH2||Constitutional mismatch repair deficiency syndrome (CMMR-D)||non-Hodgkin’s lymphoma, ALL, AML||18709565, 16341812, 24737826|
|MSH6||Constitutional mismatch repair deficiency syndrome (CMMR-D)||non-Hodgkin’s lymphoma, ALL, AML||18709565, 16341812, 24737826|
|NBN||Nijmegen breakage syndrome||ALL||11325820, 16840438|
|NF1||Neurofibromatosis type 1||Juvenile myelomonocytic leukemia (JMML), MDS||22240541, 23257896|
|PMS2||Constitutional mismatch repair deficiency syndrome (CMMR-D)||non-Hodgkin’s lymphoma, ALL, AML||18709565, 16341812, 24737826|
|RUNX1||Familial platelet disorder with propensity to myeloid malignancy||MDS, AML||18723428|
|TERC||TERC-related dyskeratosis congenita||MDS, AML||20507306, 19282459|
|TERT||TERT-related dyskeratosis congenita||MDS, AML||20507306, 19282459|
|TP53||Li-Fraumeni syndrome||ALL||23334668, 19204208, 20522432|
Most of the genes on this panel have autosomal dominant inheritance. Several other genes have autosomal recessive inheritance, or result in clinically distinct autosomal recessive conditions, as outlined below:
Carriers (heterozygotes) of many of the above autosomal recessive conditions have an increased risk for adult-onset cancers. This information will be included in the test report when a result is present.
This panel may be considered for individuals whose personal and/or family history is suggestive of a hereditary predisposition to hematologic malignancies and includes any of the following:
If the patient has undergone an allogenic bone marrow transplant (using bone marrow from a donor) prior to genetic testing or currently has a hematological malignancy with actively circulating tumor cells, testing a sample type not derived from blood (such as skin biopsy) is warranted. While we do not accept this sample type directly, we can accept gDNA derived from skin or muscle, but deletion/duplication analysis is not guaranteed for gDNA samples because the success rate varies based on sample quality. Please see our Sample requirements page for more details.
Invitae is a College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments (CLIA)-certified clinical diagnostic laboratory performing full-gene sequencing and deletion/duplication analysis using next-generation sequencing technology (NGS).
Our sequence analysis covers clinically important regions of each gene, including coding exons and 10 to 20 base pairs of adjacent intronic sequence on either side of the coding exons in the transcript listed below, depending on the specific gene or test. In addition, the analysis covers select non-coding variants. Any variants that fall outside these regions are not analyzed. Any limitations in the analysis of these genes will be listed on the report. Contact client services with any questions.
Based on validation study results, this assay achieves >99% analytical sensitivity and specificity for single nucleotide variants, insertions and deletions <15bp in length, and exon-level deletions and duplications. Invitae's methods also detect insertions and deletions larger than 15bp but smaller than a full exon but sensitivity for these may be marginally reduced. Invitae’s deletion/duplication analysis determines copy number at a single exon resolution at virtually all targeted exons. However, in rare situations, single-exon copy number events may not be analyzed due to inherent sequence properties or isolated reduction in data quality. Certain types of variants, such as structural rearrangements (e.g. inversions, gene conversion events, translocations, etc.) or variants embedded in sequence with complex architecture (e.g. short tandem repeats or segmental duplications), may not be detected. Additionally, it may not be possible to fully resolve certain details about variants, such as mosaicism, phasing, or mapping ambiguity. Unless explicitly guaranteed, sequence changes in the promoter, non-coding exons, and other non-coding regions are not covered by this assay. Please consult the test definition on our website for details regarding regions or types of variants that are covered or excluded for this test. This report reflects the analysis of an extracted genomic DNA sample. In very rare cases, (circulating hematolymphoid neoplasm, bone marrow transplant, recent blood transfusion) the analyzed DNA may not represent the patient's constitutional genome.
|Gene||Transcript reference||Sequencing analysis||Deletion/Duplication analysis|
ATM: Sequencing analysis for exons 6, 24, 43 includes only cds +/- 10 bp.
EPCAM: Sequencing analysis is not offered for this gene.
MLH1: Deletion/duplication analysis covers the promoter region. Sequencing analysis for exons 12 includes only cds +/- 10 bp.
MSH2: Analysis includes the exon 1-7 inversion (Boland mutation). Sequencing analysis for exons 2, 5 includes only cds +/- 10 bp.
MSH6: Sequencing analysis for exons 7, 10 includes only cds +/- 10 bp.
NF1: Sequencing analysis for exons 2, 7, 25, 41, 48 includes only cds +/- 10 bp.
PMS2: Sequencing analysis for exons 7 includes only cds +/- 10 bp.
TP53: Deletion/duplication analysis covers the promoter region.